American Journal of Cardiovascular Drugs 期刊简介

American Journal of Cardiovascular Drugs
英文简介:

Promoting rational therapy within the discipline of cardiology, the American Journal of Cardiovascular Drugs covers all aspects of the treatment of cardiovascular disorders, particularly the place in therapy of newer and established agents.

Via a program of reviews and original clinical research articles, the journal addresses major issues relating to treatment of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of cardiovascular disorders; and the practical management of specific clinical situations.

The American Journal of Cardiovascular Drugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.

中文简介:(来自Google、百度翻译)

促进合理治疗在心脏病学的学科内,美国心血管药物杂志涵盖了心血管疾病治疗的所有方面,特别是在治疗新的和成熟的药物的地方。
通过一个程序的评论和原始的临床研究文章,该杂志涉及与这些疾病的治疗有关的主要问题,包括主要药物类别的药理学,功效和不良反应; 有关新开发药物和药物类别的信息; 心血管疾病病因最新研究的治疗意义; 以及特定临床情况的实际管理。
《美国心血管药物杂志》提供了一系列额外的增强功能,旨在提高该杂志内容的知名度,读者人数和教育价值。每篇文章都附有要点摘要,为广大读者提供了省时的内容概述。文章可能附有简单的语言摘要,以帮助患者,护理人员和其他人了解重要的医学进展。该杂志还提供了包括各种其他类型的增强功能的选项,包括幻灯片集、视频和动画。所有增强的功能都经过同行评审,达到与文章本身相同的高标准。同行评审使用Editorial Manager® 进行,并得到国际专家数据库的支持。该数据库与其他Adis期刊共享。

期刊ISSN
1175-3277
影响指数
3.535
最新CiteScore值
5.10 查看CiteScore评价数据
最新自引率
1.40%
官方指定润色网址
https://www.deeredit.com/?type=ss1
投稿语言要求

Improve the quality of the paper, eliminate grammar and spelling errors, increase readability, ensure accurate communication of viewpoints, enhance academic reputation, and increase the chances of the paper being accepted.

建议点击这个网址:https://www.deeredit.com/?type=ss2,资深审稿专家为您评估稿件质量,提供针对性改进建议,最终可助您极大提升目标期刊录用率

期刊官方网址

hot

https://www.peipusci.com/?type=9
杂志社征稿网址

hot

https://www.peipusci.com/?type=10
通讯地址
ADIS INT LTD, 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND, NEW ZEALAND, 1311
偏重的研究方向(学科)
医学-心血管系统
出版周期
Bimonthly
出版年份
2001
出版国家/地区
NEW ZEALAND
是否OA
No
SCI期刊coverage
Science Citation Index Expanded(科学引文索引扩展)
NCBI查询
PubMed Central (PMC)链接 全文检索(pubmed central)
American Journal of Cardiovascular Drugs 期刊中科院JCR 评价数据
最新中科院JCR分区
大类(学科)
小类(学科)
综述期刊
医学
CARDIAC & CARDIOVASCULAR SYSTEMS(心脏和心血管系统)4区 PHARMACOLOGY & PHARMACY(药学)3区
最新的影响因子
3.535
最新公布的期刊年发文量
年度总发文量 研究类文章占比
95 52.63%
总被引频次 46
影响因子趋势图
近年的影响因子趋势图(整体平稳趋势)

2022年预警名单预测最新

American Journal of Cardiovascular Drugs 期刊CiteScore评价数据
最新CiteScore值
5.10
年文章数 95
SJR
1.063
SNIP
0.959
CiteScore排名
序号 类别(学科) 排名 百分位
1 Medicine Cardiology and Cardiovascular Medicine #68/317
2 Medicine Pharmacology (medical) #64/246
CiteScore趋势图
CiteScore趋势图
American Journal of Cardiovascular Drugs 相关期刊推荐
本刊同领域相关期刊
期刊名称 IF值
HERZ 1.429
HEART 5.934
EUROPACE 5.162
CARDIOLOGY 1.85
CIRCULATION 29.393
HEART & LUNG 2.188
HEART RHYTHM 6.28
KARDIOLOGIYA 0.391
PERFUSION-UK 1.952
本刊同分区等级的相关期刊
期刊名称 IF值
CIRCULATION JOURNAL 2.963
CLINICAL CARDIOLOGY 2.853
RESPIRATORY MEDICINE 3.381
Journal of Cardiology 3.127
Cardiovascular Toxicology 3.199
Cardiovascular Therapeutics 2.993
AMERICAN JOURNAL OF CARDIOLOGY 2.75
CURRENT PROBLEMS IN CARDIOLOGY 5.148
Hellenic Journal of Cardiology 3.807
American Journal of Cardiovascular Drugs 投稿经验(由下方点评分析获得,1人参与,1188人阅读)
投稿录用比例: 较易
审稿速度: >12周,或约稿
分享者 点评内容
没有更多了~
Copyright © 2014-2019 晟斯医学 All Rights Reserved. 备案号:苏ICP备11037034号-5 版权所有:南京孜文信息咨询有限公司